|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings GP/FP/Primary care






Internal medicine 





Cardiology 





Key Words: angioplasty (transluminal, percutaneous coronary) coronary disease myocardial infarction
| The first 150 words of the full text of this article appear below. |
METHODS
Design:
randomised controlled trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).
Allocation:
unclear allocation concealment.*
Blinding:
blinded (outcome adjudication committee).*
Follow up period:
median 4.6 years (range 2.5–7.0 y).
Setting:
50 centres in the US and Canada.
Patients:
2287 patients (mean age 62 y, 85% men) with stable CAD (stenosis
70% in
1 proximal epicardial coronary artery and objective evidence of myocardial ischaemia, or
1 coronary stenosis
80% and classic angina without provocative testing). Exclusion criteria included persistent class IV angina, a markedly positive stress test, refractory heart failure or cardiogenic shock, ejection fraction <30%, revascularisation in
6 months, and coronary anatomy not suitable for PCI.
Intervention:
PCI (with bare metal stents in most patients) plus OMT (anti-ischaemic therapy, aggressive therapy to optimise lipid levels, and a lifestyle intervention) (n = 1149) or OMT alone (n = 1138).
Outcomes:
composite end point of death or non-fatal myocardial
Bertram Pitt, MD
University of Michigan School of Medicine, Ann Arbor, Michigan, USA
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |